


Claims Listing

The following listing replaces all previous claims listings and incorporates the amendments submitted in the present paper

1. (Currently amended) A purified compound of formula I




wherein R_1 , R_2 , R_3 , R_4 are all or partly hydrogen atoms, or alkyl containing 1 to 5 carbon atoms; ~~and~~ or pharmaceutically acceptable salts thereof ~~free from cotton seed tissue~~.

2. (Original) Compound of formula I according to claim 1, wherein R_1 , R_2 , R_3 , R_4 are all hydrogen atoms.

3. (Original) Compound of formula I according to claim 2, characterized in that the compound is derived from cottonseeds.

4. (Currently amended) Compound of formula I according to claim 1, which is ~~quercetin-3-O- β -D-apiofuranosyl-(1 \rightarrow 2)-[α -D-rhamnopyranosyl-(1 \rightarrow 6)]- β -D-glucopyranoside~~
quercetin-3-O- β -D- apiofuranosyl-(1 \rightarrow 2)-[α -D-rhamnopyranosyl-(1 \rightarrow 6)]- β -D- glucopyranoside.

5. (Previously presented) A pharmaceutical composition comprising compound of formula I,



wherein R₁, R₂, R₃, R₄ are all or partly hydrogen atoms, or alkyl containing 1 to 5 carbon atoms; and a pharmaceutical carrier.


6. (Previously presented) Pharmaceutical composition according to claim 5, for the treatment of diseases or symptoms related to 5HT_{1A} receptor,.

7. (Previously presented) Pharmaceutical composition according to claim 5, for protection of neuron cells.

8. (Previously presented) Pharmaceutical composition according to claim 5, wherein the pharmaceutical carriers are adjuvants for use in solid medicaments including disintegrants, diluting agents, binders, lubricants, etc, and those for use in liquid medicaments including solvents, pH adjusting agents, osmotic regulators, antioxidants, metal complexing agents, preservatives, flavoring agents, and mixtures thereof.

9. (Original) Pharmaceutical composition according to claim 5, wherein R_1 , R_2 , R_3 , R_4 of formula I are all hydrogen atoms.

10. (Currently amended) Method of treating a disease related to 5HT_{1A} acceptor or for protection of neuron cells which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula I,



wherein R_1 , R_2 , R_3 and R_4 are all or partly hydrogen atoms or alkyl containing 1 to 5 carbon atoms.

11. (Previously presented) Method according to claim 10, wherein R_1 , R_2 , R_3 , R_4 of formula I are all hydrogen atoms.

12 (Previously presented) Pharmaceutical composition according to claim 5 wherein the pharmaceutical carrier comprises an adjuvant for use in solid medicaments.

13 (Canceled)

14. (Canceled)

15 (Canceled)

16(Previously presented) Pharmaceutical composition according to claim 12 wherein said adjuvant is selected from disintegrants, diluting agents, binders, lubricants or mixtures thereof

17 (Previously presented) Pharmaceutical composition according to claim 5 wherein the pharmaceutical carrier comprises an adjuvant for use in liquid medicaments

18 (Previously presented) Pharmaceutical composition according to claim 17 wherein said adjuvant is selected from solvents, pH adjusting agents, osmotic regulators, antioxidants, metal complexing agents, preservatives, flavoring agents or mixtures thereof.